Evidence map›Paper›PMID 35563759›Full record

ReviewCells2022

How CAR T Cells Breathe.

Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Determination of CAR T cell metabolism in an optimized protocol.Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Christopher ForcadosTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.
Sandy JoaquinaTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.
Nicholas Paul CaseyTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.ORCID 0000-0001-6706-8710
Benjamin CaulierTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.ORCID 0000-0002-7170-9194
Sébastien WälchliTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.ORCID 0000-0001-5869-1746
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism. T cells tend to adopt diverse metabolic profiles depending on their differentiation state and their stimulation level. It is therefore expected that the introduction of a synthetic molecule such as CAR, activating endogenous signaling pathways, will affect metabolism. In addition, upon patient treatment, the tumor microenvironment might influence the CAR T cell metabolism by compromising the energy resources. The access to novel technology with higher throughput and reduced cost has led to an increased interest in studying metabolism. Indeed, methods to quantify glycolysis and mitochondrial respiration have been available for decades but were rarely applied in the context of CAR T cell therapy before the release of the Seahorse XF apparatus. The present review will focus on the use of this instrument in the context of studies describing the impact of CAR on T cell metabolism and the strategies to render of CAR T cells more metabolically fit.

Indexed as

Receptors, Chimeric AntigenGlycolysisHumansImmunotherapy, AdoptiveT-LymphocytesTumor MicroenvironmentReceptors, Chimeric AntigenCARchimeric antigen receptormetabolismT cellstonic signaling

Identifiers

PMID35563759
PMCPMC9102061
OpenAlexW4224436737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.